Yuanning Zheng
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (25)
Year:
2026
Non–small cell lung cancer (NSCLC) constitutes over 80% of lung cancer cases and remains a leading cause of cancer-related mortality worldwide. Despite the advent of immune checkpoint inhibitors, their efficacy is limited to 27 to 45% of patients. Identifying likely treatment responders is essential for optimizing healthcare and improving quality of life. We generated multiplex immunofluorescence (mIF) images, histopathology, and RNA sequencing data from human NSCLC tissues. Through the analysis of mIF images, we characterized the spatial organization of 1.5 million cells based on the expression levels for 33 biomarkers. To enable large-scale characterization of tumor microenvironments, we developed NucSegAI, a deep learning model for automated nuclear segmentation and cellular classification in histology images. With this model, we analyzed the morphological, textural, and topological phenotypes of 45.6 million cells across 119 whole-slide images. Through unsupervised phenotype discovery, we identified specific lymphocyte phenotypes predictive of immunotherapy response. Our findings can improve patient stratification and guide selection of effective therapeutic regimens.
Year:
2025
A substantial proportion of patients with non-metastatic triple-negative breast cancer (TNBC) experience disease progression and death despite treatment. However, no tool currently exists to discriminate those at higher risk of death. To identify high-risk TNBC, we conducted a retrospective analysis of 749 patients from two independent cohorts. We built a prediction model that leverages breast magnetic resonance imaging (MRI) features to predict risk groups based on a 50-gene Transcriptomics Signature (TS). The TS distinguished patients with high-risk for death in multivariate survival analysis (Transcriptomic cohort: [HR] = 13.6, 95% confidence interval [CI] = 1.56-1, p = 0.02; SCAN-B cohort: HR = 1.45, CI 1.04-2.03, p = 0.02). The model identified a 20-feature radiomic signature derived from breast MRI that predicted the TS-based risk groups. This imaging-based classifier was applied to a validation cohort (log rank p = 0.013, accuracy 0.72, AUC 0.71, F1 0.74, precision 0.67, and recall 0.82), detecting a 25% absolute survival difference between high- and low-risk groups after 5 years.
Year:
2025
Year:
2025
Glioblastoma (GBM) is a highly vascularized, heterogeneous tumor, yet antiangiogenic therapies have yielded limited survival benefits. The lack of validated predictive biomarkers for treatment response stratification remains a major challenge. Aminoacyl tRNA synthetase complex–interacting multicomplex proteins (AIMP) 1/2/3 have been implicated in central nervous system diseases, but their roles in gliomas remain unexplored. We investigated their association with angiogenesis and their significance as predictive biomarkers for antiangiogenic treatment response. In this multi-cohort retrospective study, we analyzed glioma samples from The Cancer Genome Atlas, Chinese Glioma Genome Atlas, REMBRANDT, Gravendeel, BELOB, and REGOMA trials, and four single-cell transcriptomic datasets. Multiomic analyses incorporated transcriptomic, epigenetic, and proteomic data. Kaplan–Meier and Cox proportional hazards models were used to assess the potential prognostic value of AIMPs in heterogeneous and homogeneous treatment groups. Using single-cell transcriptomics, we explored spatial and cell type–specific AIMP2 expression in GBM. AIMP1/2/3 expressions correlated significantly with angiogenesis across The Cancer Genome Atlas cancers. In gliomas, AIMPs were upregulated in tumor versus normal tissues, higher- versus lower-grade gliomas, and recurrent versus primary tumors (P < 0.05). Upon retrospective analysis of two clinical trials assessing different antiangiogenic drugs, we found that high-AIMP2 subgroups had improved response to therapies in GBM [REGOMA: HR, 4.75 (1.96–11.5), P < 0.001; BELOB: HR, 2.3 (1.17–4.49), P = 0.015]. AIMP2-cg04317940methylation emerged as a clinically applicable stratification marker. Single-cell analysis revealed homogeneous AIMP2 expression in tumor tissues, particularly in astrocyte-like cells, suggesting a mechanistic link to tumor angiogenesis. These findings provide novel insights into the role of AIMPs in angiogenesis, offering improved patient stratification and therapeutic outcomes in recurrent GBM. Significance: This study identifies AIMP2 as a novel biomarker predictive of antiangiogenic treatment response in recurrent GBM. Through multiomic and single-cell analyses, AIMP2 is shown to be upregulated in aggressive gliomas and linked to angiogenesis. Its expression and methylation status offer a clinically applicable stratification tool, enabling more personalized therapeutic approaches and improved outcomes in patients receiving antiangiogenic therapies.
Year:
2025
Cancer involves dynamic changes caused by (epi)genetic alterations such as mutations or abnormal DNA methylation patterns which occur in cancer driver genes. These driver genes are divided into oncogenes and tumor suppressors depending on their function and mechanism of action. Discovering driver genes in different cancer (sub)types is important not only for increasing current understanding of carcinogenesis but also from prognostic and therapeutic perspectives. We have previously developed a framework called Moonlight which uses a systems biology multi-omics approach for prediction of driver genes. Here, we present an important development in Moonlight2 by incorporating a DNA methylation layer which provides epigenetic evidence for deregulated expression profiles of driver genes. To this end, we present a novel functionality called Gene Methylation Analysis (GMA) which investigates abnormal DNA methylation patterns to predict driver genes. This is achieved by integrating the tool EpiMix which is designed to detect such aberrant DNA methylation patterns in a cohort of patients and further couples these patterns with gene expression changes. To showcase GMA, we applied it to three cancer (sub)types (basal-like breast cancer, lung adenocarcinoma, and thyroid carcinoma) where we discovered 33, 190, and 263 epigenetically driven genes, respectively. A subset of these driver genes had prognostic effects with expression levels significantly affecting survival of the patients. Moreover, a subset of the driver genes demonstrated therapeutic potential as drug targets. This study provides a framework for exploring the driving forces behind cancer and provides novel insights into the landscape of three cancer sub(types) by integrating gene expression and methylation data.
Year:
2025
Accurately labeling large datasets is important for biomedical machine learning yet challenging while modern data augmentation methods may generate noise in the training data, which may deteriorate machine learning model performance. Existing approaches addressing noisy training data typically rely on strict modeling assumptions, classification models and well-curated dataset. To address these, we propose a novel reliability-based training-data-cleaning method employing inductive conformal prediction (ICP). This method uses a small set of well-curated training data and leverages ICP-calculated reliability metrics to selectively correct mislabeled data and outliers within vast quantities of noisy training data. The efficacy is validated across three classification tasks with distinct modalities: filtering drug-induced-liver-injury (DILI) literature with free-text title and abstract, predicting ICU admission of COVID-19 patients through CT radiomics and electronic health records, and subtyping breast cancer using RNA-sequencing data. Varying levels of noise to the training labels were introduced via label permutation. Our training-data-cleaning method significantly enhanced the downstream classification performance (paired t-tests, p ≤ 0 . 05 among 30 random train/test partitions): significant accuracy enhancement in 86 out of 96 DILI experiments (up to 11.4% increase from 0.812 to 0.905), significant AUROC and AUPRC enhancements in all 48 COVID-19 experiments (up to 23.8% increase from 0.597 to 0.739 for AUROC, and 69.8% increase from 0.183 to 0.311 for AUPRC), and significant accuracy and macro-average F1-score improvements in 47 out of 48 RNA-sequencing experiments (up to 74.6% increase from 0.351 to 0.613 for accuracy, and 89.0% increase from 0.267 to 0.505 for F1-score). The improvement can be both statistically and clinically significant for information retrieval, disease diagnosis and prognosis. The method offers the potential to substantially boost classification performance in biomedical machine learning tasks without necessitating an excessive volume of well-curated training data or strong data distribution and modeling assumptions in existing semi-supervised learning methods.
Year:
2025
AIMP1/2/3 correlates with angiogenesis pathway gene sets. Correlation between AIMP1/2/3 mRNA expression in 33 TCGA cancers and ( A ) 141 Panther pathway “angiogenesis gene set” and ( B ) 76 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway “VEGF Signaling pathway” gene set. The color map represents Pearson correlation coefficient R values. *asterisk represents statistically significant correlation ( P
Year:
2025
Bevacizumab treatment response is associated with specific AIMP CpG site methylation status in gliomas. A, Significant association between two CpG sites and astrocytoma ( n = 22) pathologic response to bevacizumab treatment. A Student t test P value B , Forest plots depicting Cox proportional hazards model univariate ( i ) and multivariate ( ii ) analysis for the effects of AIMP1/2/3 CpG methylation status in GBM ( n = 27) and astrocytoma ( n = 24).
Year:
2025
Spatial and cell type–specific expression of AIMP2 in GBM tumors. A, Spatial distribution of AIMP2 expression across tumor tissues in two representative GBM slides ( i : slide 334_T and ii : slide 268_T) analyzed using a spatial transcriptomic dataset. The heatmaps display homogeneous expression of AIMP2 with varying intensity from low (purple) to high (yellow), indicating the absence of localized expression hotspots. B, Violin plots representing AIMP2 expression across GBM cellular subtypes. i, AIMP2 expression in key GBM subtypes, including MES-like, AC-like, oligodendrocyte progenitor cell (OPC)–like, and neural progenitor cell (NPC)–like cells from a concatenated single-cell RNA-seq cohort (Kruskal–Wallis P = 2.32e−02). ii, AIMP2 expression across malignant GBM subtypes from a spatial transcriptomic dataset. (Kruskal–Wallis P = 1.32e−03).
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (11)
Christoph Sadée
Stanford University
David Kaul
-
Ravi Madduri
Senior Scientist
Argonne National Laboratory
James Ford
Professor
Stanford University
Maximilian Gertler
-
Olivier Gevaert
Assistant Professor
Stanford University
Emmanuel Spanakis
Precision Medicine Data Scientist
Sanofi-Aventis Recherche et Developpement Vitry-sur-Seine Alfortville
Brooke E. Howitt
Stanford University School of Medicine
Haruka Itakura
Assistant Professor of Medicine
Stanford University
Melinda L Telli
Professor of Medicine
Stanford University School of Medicine
Jeanne Shen
Associate Professor
Stanford University
Make your next move.
Prepare your application
Review drafts before you send them.